Search is Powered by Google
Cancer / Oncology News

Consumer Advocacy Groups, Pharmaceutical Companies Debate Three-Year Marketing Exclusivity Period Awarded By FDA For Plan B

Main Category: Cancer / Oncology
Also Included In: Women's Health / Gynecology;  Pediatrics / Children's Health
Article Date: 15 Nov 2006 - 17:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Consumer advocates and drug companies are debating FDA's decision to grant Barr Pharmaceuticals three years of regulatory exclusivity for its emergency contraceptive Plan B, which can prevent pregnancy if taken up to 72 hours after sexual intercourse, the Boston Globe reports. In exchange for exclusivity -- in which the drug will receive no generic competition for a certain period of time -- Barr must conduct a series of studies to determine how consumers use the product and how they understand the new label. Melissa Dunn, a spokesperson for GlaxoSmithKline Consumer Healthcare, said exclusivity provides "some incentive for innovation," adding, "It's really for companies who are doing all of the background research, investing the [research and development] dollars, and time and efforts into developing a product to give them some protection for a period of time." GSK received three years of exclusivity for over-the-counter sales of the smoking cessation drug Nicorette. Sidney Wolfe, director of the Health Research Group at Public Citizen, said the exclusivity means that consumers will have to pay more for the drug than they should, adding that pharmaceutical companies "should get some advantage for" their research, "but it seems like three years is on the long side." Democratic lawmakers, who will hold the majority in the 110th Congress, have said they will seek some restrictions in the methods drug makers use to keep generic competition off the market (Boston Globe, 11/13).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Nicorette.





Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...